Summarv A quantitatise polvmerase chain reaction (PCR) method for determining concentrations of mRN.A for the cyclic AMP (cAMP)-binding protein RI alpha. a regulatory subum't of cAMP-dependent protein kinase.
the same primers as the target mRNA and differed in sequence by only four bases. As only one of these base changes results in a purine pyrimidine sWitch the effective change in labelling with [3-P] dCTP A-as less than 0.50O. Reverse transcription of mRNA was performed and quantitatisve PCR was carried out using fixed levels of mutant RI alpha *s varying amounts of both normal RI alpha sequence of know-n concentration and unknown samples. Validation of the technique using rigourous quality control established that reverse transcription. determined by incorporation of labelled nucleotides. gave intra-and interassay sariations of 16.2 and 9.3°o respectixely. Using crossover evaluation of cDNA concentrations with cloned RI alpha sequences as controls intra-and interassay variations of 14.3°o and 4-8°o respectiselv were obtained. Using (Battersby et al.. 1994 : Miller et al.. 1993a . Recent studies have shown that high levels of total binding are concomitant with a relative overexpression of the RI subtype (Miller et al.. 1993b The results of a typical assay are shown (Figure 2) . Following co-amplification and restriction digestion of cloned cDNA from both mutant and normal RI alpha inserts two bands are clearly visible on the autoradiograph (Figure 2 ). The sizes of these bands correspond to PCR products of 430 and 215 bp respectively. In the absence of any normal cDNA (lane 14) all cDNA is cleaved to form a 215 bp product. In the absence of mutant cDNA no cleavage of the 430 bp normal fragment is observed (data not shown).
In the assay shown (Figure 2 ), mutant RI alpha cDNA is co-amplified in decreasing concentrations with known (lanes 1-8) or unknown (lanes 10-13) concentrations of normal RI alpha cDNA. At high concentrations of mutant RI alpha cDNA the 215 bp band, representing the cleaved mutant PCR amplimer, represents the major PCR product. As the concentration of mutant RI alpha cDNA is decreased the relative intensity of the 215 bp band decreases; also the intensity of the 430 bp band, representing unmutated RI alpha cDNA, increases until a point is reached where RI alpha normal cDNA represents the majority of the PCR template. At this point the intensity of the two bands is reversed with the lower band becoming less intense than the higher. This 'cross-over' point represents the point at which the two templates are present at equal concentrations within the PCR reaction tube and therefore are equally susceptible to PCR amplification. The approximate concentration of RI alpha cDNA can be estimated from the gel shown here (Figure 2 ). More precise quantitation is achieved by excising the radiolabelled bands, counting the incorporated [32P]dCTP and plotting the incorporated counts for each band against the concentration of added mutant RI alpha cDNA ( Figure  3 ). This method allows an estimation of the theoretical crossover point for the PCR reaction, giving a more precise value for the concentration of RI alpha cDNA in the unknown sample.
Assay sensitivity and limit of detection
Standard assay conditions were established using a range of cDNA concentrations from 34 fmol to 3.4 amol (10-14-10l0 M, 100-0.1 pg) RI alpha mutant cDNA. Using these conditions the limit of sensitivity was approximately 10 amol (1.0 pg DNA). By decreasing the range of controls used to establish the unknown concentration (to between 10 and (Table I ). In addition, variation between assays can be controlled to within 10% for individual samples. This allows the use of a more simple cDNA PCR quantitation rather than the use of control RNA from the mutated cDNA product for inclusion within the reverse transcription reaction. This approach, which is theoretically more accurate, requires measurement of significantly more samples per patient to provide accurate quantitation.
Intra-and interassay coefficients of variation have been investigated in the PCR stage of the assay to establish the potential limitations of accuracy for this technique. Using the methods described above intra-assay variation was 14.3% whereas interassay variation remained below between 4% and 8%, for low and high controls, over eight assays. Standard radioimmunoassays (RIAs) will commonly have intra-and interassay variations between 5% and 12%. In our view while this technique is as yet less consistent than RlAs the variation observed shows that differences in mRNA expression of greater than 50% will be readily detected using this system. By using the errors involved in both the reverse transcription assays and the PCR reaction confidence intervals for values obtained were calculated as the obtained value + 31% or -27%. This compares favourably with conventional steroid assays involving extraction and immunoassay with confidence intervals of around +20% (Bartlett et al., 1987 (Bartlett et al., , 1989 . These calculations do not control for systematic errors which could be highly reproducible, however we have not identified any such source of error in our system. In tumour tissue from a limited series of patients we have shown changes in mRNA levels ranging from decreases of up to 99% to increases of over 4000%. This suggests that for the mRNA species for which this assay was designed the accuracy and reproducibility observed in this study provide an acceptable measurement of mRNA changes in these samples.
In common with other studies (JessenEller et al., 1994; Izutani et al., 1994) (Bianchi et al., 1994) , disease prognosis and treatment (Seeger et al., 1985; Brodeur et al., 1984) and drug resistance (Withoff et al., 1994; Lyttelton et al., 1994) al., 1994; Chan et al., 1994; Lubin et al., 1991; Siebert and Larrick, 1992; Frye et al., 1989) .
In order to avoid these problems, many researchers have made use of mutated PCR products to provide controls within PCR vessels. The aim of these methods has been to circumvent the problems associated with primer sets with differing annealing efficiencies and to provide a more accurate standard for the quantitation of DNA levels. The use of PCR products which have been altered by the insertion of 100-200 bp of random DNA between the primer binding sites provided a significant improvement in terms of reproducibility and quantitation of DNA species. By eliminating the requirement for a competitive PCR template to be included, the problems associated with separate primer sites were removed. This approach would appear to circumvent the problems of unequal amplification efficiencies caused by differing primer sets. However, it is known that products of differing size within a single PCR will show preferential amplification of the smaller product (Underwood et al., 1994; Chan et al., 1994; Frye et al., 1989) . Such amplification errors can result in ratios of products varying by up to 300% over 25-35 cycles (Withoff et al., 1994; Frye et al., 1989) when different regions of a single gene are amplified. A theoretical variation of amplification efficiency of as little as 3% can result in a 2 to 3-fold difference in end product ratios. Use of internal labelling of PCR products can further compound such errors as larger PCR products will by nature include more labelling sites than shorter ones (Frye et al., 1989) .
As these problems were appreciated and as the potential for PCR-based assays for use in clinical management of disease become more apparent the need for an accurate, quantitative and potentially automatable system was clear.
Such a system has been developed with the use of sitedirected mutagenesis of PCR products to provide a PCR control template that has minimal modifications in sequence to introduce a novel restriction enzyme site within the PCR product. With primer sites and size identical to the target sequence this product (control) can then be differentiated from the unknown following a simple enzymatic digestion.
The advantages of this system are that by maintaining maximum identity between the control (mutated form) and sample (normal form) DNA the reaction kinetics for both products are essentially identical, and so minimise errors due to the PCR reaction itself. In this study a variation in sequence reflecting one base change (0.2%) was achieved. Such an approach maxises the potential for accuracy of PCR quantitation. Furthermore, while it is possible to use conventional size separation to distinguish the control and sample PCR products, as in this preliminary study, the use of biotinylated and fluorescence-based primers would allow this system to be automated for use on a plate-reader system or on an automated DNA sequencer. This flexibility provides the potential for the development of automated PCR-based assay systems that have the potential for application within the clinical environment using established technologies. In the light of these possibilities, and since the experimental systems under investigation required the ability to accurately quantify mRNA from tumour specimens this approach was used to evaluate the use of quantitative PCR as a potential diagnostic tool.
In breast cancer patients high levels of tumour cDNAbinding proteins have been shown to be associated with poor prognosis in terms of both disease recurrence and overall survival (Battersby et al., 1994; Miller et al., 1993a) . This association is independent of known established prognostic factors and allows the identification of a small subgroup of patients whose outlook warrants the implementation of aggressive systemic therapy. Further investigations suggest that differential expression of certain forms of cAMP-binding protein are of significance in producing this relationship (Battersby et al., 1994; Miller et al., 1993a; Miller et al., 1993b) . Moreover, whereas measurement of binding protein levels requires large amounts of tissue, it should be possible to determine mRNA levels for specific cAMP-BP isoforms in small (FNA) samples of breast tissue. The relationship between these parameters is currently under investigation. This could provide a rapid and robust method for evaluating the relationships between RI alpha expression, disease response to treatment and the usefulness of aggressive therapies. Using the quantitative PCR system described above, mRNA levels have been assessed in breast cancer patients and differences in RI alpha expression identified, the clinical significance of which will be further evaluated.
In conclusion, this study has demonstrated that, with the inclusion of adequate quality control assessment and by appropriate design, PCR can be used as a practical laboratory procedure when accuracy and reproducibility as well as high level throughput are required. The methods described here can be applied to the measurement of any DNA or mRNA species for which a clinical demand becomes apparent. Ongoing studies using this method are designed to probe breast cancer patients to establish the clinical importance of the specific mRNA species used in these studies.
